Peter Altman, President and CEO of BioCardia, Inc. (NASDAQ:BCDA), purchased shares of the company’s common stock on May 15, 2026. Altman acquired a total of 5,100 shares for $5,202.
The transactions were executed in multiple trades, with prices ranging from $1.01 to $1.03 per share. The reported price of $1.02 per share reflects the weighted average. BioCardia shares are trading near their 52-week low of $1.00, down 56% over the past year.
Following these acquisitions, Altman directly holds 285,866 shares. According to Bond.az analysis, the stock appears undervalued at current levels. Investors can access additional tips and financial metrics to better understand BioCardia’s potential.
In other recent news, BioCardia reported its first-quarter 2026 earnings, highlighting operational improvements and strategic clinical advancements. The company is focusing on reducing expenses while advancing its CardiAMP cell therapy program. BioCardia currently holds a cash position of $951,000 and plans to secure additional funding to support ongoing trials and regulatory submissions.
